Stay updated on Eribulin/Pembrolizumab in HR+ Metastatic Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Eribulin/Pembrolizumab in HR+ Metastatic Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Eribulin/Pembrolizumab in HR+ Metastatic Breast Cancer Clinical Trial page

  1. Check
    today
    Change Detected
    Summary
    The revision label on the page has been updated from v3.5.3 to v3.5.4, signaling a newer version of the document. This change reflects an updated version identifier rather than any user-facing content edits.
    Difference
    0.1%
    Check dated 2026-05-15T14:22:34.000Z thumbnail image
  2. Check
    7 days ago
    No Change Detected
  3. Check
    14 days ago
    No Change Detected
  4. Check
    22 days ago
    Change Detected
    Summary
    The page footer revision/version was updated from v3.5.2 to v3.5.3, indicating a site release/version change rather than an update to the clinical study record details.
    Difference
    0.1%
    Check dated 2026-04-24T06:09:23.000Z thumbnail image
  5. Check
    29 days ago
    Change Detected
    Summary
    Added Revision: v3.5.2; Deleted Revision: v3.5.0.
    Difference
    0.1%
    Check dated 2026-04-17T02:31:53.000Z thumbnail image
  6. Check
    58 days ago
    Change Detected
    Summary
    Revision: v3.5.0 was added and Revision: v3.4.3 was removed from the page header.
    Difference
    0.1%
    Check dated 2026-03-18T22:41:07.000Z thumbnail image
  7. Check
    65 days ago
    Change Detected
    Summary
    Revision: v3.4.3; no visible changes to study content.
    Difference
    0.1%
    Check dated 2026-03-11T18:12:29.000Z thumbnail image
  8. Check
    94 days ago
    Change Detected
    Summary
    A new site revision label Revision: v3.4.2 appears and a prior government-funding status notice is removed. These are general site-wide UI updates and do not affect the study details or eligibility criteria.
    Difference
    0.4%
    Check dated 2026-02-11T05:34:37.000Z thumbnail image

Stay in the know with updates to Eribulin/Pembrolizumab in HR+ Metastatic Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Eribulin/Pembrolizumab in HR+ Metastatic Breast Cancer Clinical Trial page.